BEAM vs. SRPT, PCVX, ASND, QGEN, ROIV, TLX, RVMD, BBIO, LEGN, and AXSM
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Roivant Sciences (ROIV), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.
Beam Therapeutics vs.
Sarepta Therapeutics (NASDAQ:SRPT) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Sarepta Therapeutics received 1407 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 75.22% of users gave Sarepta Therapeutics an outperform vote while only 56.19% of users gave Beam Therapeutics an outperform vote.
In the previous week, Beam Therapeutics had 7 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 41 mentions for Beam Therapeutics and 34 mentions for Sarepta Therapeutics. Beam Therapeutics' average media sentiment score of 0.42 beat Sarepta Therapeutics' score of 0.32 indicating that Beam Therapeutics is being referred to more favorably in the news media.
Beam Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sarepta Therapeutics currently has a consensus price target of $173.52, indicating a potential upside of 69.74%. Beam Therapeutics has a consensus price target of $51.00, indicating a potential upside of 96.68%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Sarepta Therapeutics.
Sarepta Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.
Sarepta Therapeutics has a net margin of 7.43% compared to Beam Therapeutics' net margin of -41.07%. Sarepta Therapeutics' return on equity of 11.00% beat Beam Therapeutics' return on equity.
Summary
Sarepta Therapeutics beats Beam Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BEAM) was last updated on 3/3/2025 by MarketBeat.com Staff
